Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,036,045.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $530.11, for a total transaction of $5,036,045.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $171,990,478.73. This trade represents a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $501.27 on Friday. The firm’s 50-day moving average price is $536.95 and its 200-day moving average price is $535.97. The company has a market capitalization of $21.50 billion, a PE ratio of 17.93, a P/E/G ratio of 1.73 and a beta of 0.59. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the firm posted $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. Equities analysts anticipate that United Therapeutics Corporation will post 26.32 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Torren Management LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in United Therapeutics in the 4th quarter worth about $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, July 31st. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. Finally, Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.